These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 29110140)
1. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix Najafzadeh M; Garces JA; Maciel A Pharmacoeconomics; 2017 Dec; 35(12):1297-1310. PubMed ID: 29110140 [TBL] [Abstract][Full Text] [Related]
2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. Tanner JA; Davies PE; Overall CC; Grima D; Nam J; Dechairo BM Pharmacogenomics; 2020 Jun; 21(8):521-531. PubMed ID: 32301648 [No Abstract] [Full Text] [Related]
5. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Benitez J; Cool CL; Scotti DJ Per Med; 2018 Nov; 15(6):481-494. PubMed ID: 30256179 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. Celano CM; Healy B; Suarez L; Levy DE; Mastromauro C; Januzzi JL; Huffman JC Value Health; 2016; 19(2):185-91. PubMed ID: 27021752 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States. Ross EL; Zivin K; Maixner DF JAMA Psychiatry; 2018 Jul; 75(7):713-722. PubMed ID: 29800956 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Wu AC; Gay C; Rett MD; Stout N; Weiss ST; Fuhlbrigge AL Pharmacogenomics; 2015; 16(6):591-600. PubMed ID: 25880024 [TBL] [Abstract][Full Text] [Related]
9. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540 [TBL] [Abstract][Full Text] [Related]
10. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. Bradley P; Shiekh M; Mehra V; Vrbicky K; Layle S; Olson MC; Maciel A; Cullors A; Garces JA; Lukowiak AA J Psychiatr Res; 2018 Jan; 96():100-107. PubMed ID: 28992526 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of treatments for major depression in primary care practice. Lave JR; Frank RG; Schulberg HC; Kamlet MS Arch Gen Psychiatry; 1998 Jul; 55(7):645-51. PubMed ID: 9672056 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Hornberger J; Li Q; Quinn B Am J Manag Care; 2015 Jun; 21(6):e357-65. PubMed ID: 26247576 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Thompson AJ; Newman WG; Elliott RA; Roberts SA; Tricker K; Payne K Value Health; 2014; 17(1):22-33. PubMed ID: 24438714 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of alternative treatments for depression in low-income women. Beil H; Beeber LS; Schwartz TA; Lewis G J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203 [TBL] [Abstract][Full Text] [Related]
15. The costs and benefits of enhanced depression care to employers. Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497 [TBL] [Abstract][Full Text] [Related]